Glenmark Pharmaceuticals Limited (BOM:532296)
India · Delayed Price · Currency is INR 2,301.40
+19.15 (0.84%)
At close: Jul 13, 2026
Glenmark Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 12 analysts polled by S&P Global, Glenmark Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of ₹2,497. The average 1-year stock price forecast is 8.51% higher than the current stock price, while the lowest is ₹2,100 (-8.75%) and the highest is ₹2,750 (+19.49%).
Price Target: ₹2,497 (+8.51%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Glenmark Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Jan '26 | Feb '26 | Mar '26 | Apr '26 | Jun '26 | Jul '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 7 | 7 | 7 | 6 | 6 |
| Buy | 2 | 3 | 3 | 2 | 3 | 4 |
| Hold | 1 | 1 | 1 | 1 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 1 | 1 | 1 | 1 | 0 | 0 |
| Total | 12 | 12 | 12 | 11 | 11 | 12 |
Financial Forecast
Revenue This Year
166.72B
from 169.83B
Decreased by -1.83%
Revenue Next Year
185.36B
from 166.72B
Increased by 11.18%
EPS This Year
81.04
from 103.32
Decreased by -21.57%
EPS Next Year
98.29
from 81.04
Increased by 21.29%
EPS and Forward PE are based on non-GAAP adjusted numbers. Financial currency is INR.
Revenue Forecast
| Revenue | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 185.4B | ||
| Avg | 166.7B | ||
| Low | 150.4B |
Revenue Growth
| Revenue Growth | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 9.2% | ||
| Avg | -1.8% | ||
| Low | -11.4% |
EPS Forecast
| EPS | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | 89.95 | ||
| Avg | 81.04 | ||
| Low | 60.40 |
EPS Growth
| EPS Growth | 2027 | 2028 | 2029 |
|---|---|---|---|
| High | -12.9% | ||
| Avg | -21.6% | ||
| Low | -41.5% |